Redefining Hormone Sensitive Disease in Advanced Prostate Cancer

Abstract EN

Prostate cancer is the most common cancer among men in the United States.

For decades, the cornerstone of medical treatment for advanced prostate cancer has been hormonal therapy, intended to lower testosterone levels, known as Androgen Deprivation Therapy (ADT).

The development of hormone-resistant prostate cancer (now termed castration-resistant prostate cancer:CRPC) remains the key roadblock in successful long-term management of prostate cancer.

New advancements in medical therapy for prostate cancer have added to the hormonal therapy armamentarium.

These new therapeutic agents not only provide a survival benefit but also show potential for reversing hormonal resistance in metastatic CRPC, and thus redefining hormonally sensitive disease.